Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46825 | 0.79 | MEN1 (0.36) | NPY5RMAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL46821 | 0.72 | MEN1 (0.35) | NPY5RMAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL46582 | 0.66 | SLC34A2 (0.38) | MAPTMEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL47072 | 0.60 | MEN1 (0.41) | NPY5RMAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL15444454 | 0.58 | HSPH1 (0.44) | MAPTMEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL519396 | 0.58 | MEN1 (0.70) | MAPTMEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL16780930 | 0.56 | LMNA (0.60) | MAPTMEN1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2465777 | 0.55 | ALDH1A1 (0.52) | — | |
| SCHEMBL27836781 | 0.55 | MAPT (0.42) | NPY5RMAPTMEN1CYP1A2CYP3A4 | |
| SCHEMBL518582 | 0.55 | GAA (0.68) | MAPTMEN1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | NPY5R 3940/4885MAPT 3270/4885MEN1 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.